Premium
Effect of Irinotecan (CPT‐11) on fatty acid status in rats with colorectal cancer
Author(s) -
Krishnamurthi Veena,
Pawlowicz Megan,
Xue Hongyu,
Baracos Vickie,
Clandinin M.Thomas,
Mazurak Vera C
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.679
Subject(s) - irinotecan , colorectal cancer , medicine , fatty acid , fatty liver , chemotherapy , chemistry , endocrinology , cancer , gastroenterology , biochemistry , disease
Chemotherapy drugs may cause profound changes in fatty acid metabolism. Irinotecan (CPT‐11) is currently used for treatment of colorectal cancer. This study characterized amount and types of fatty acids in phospholipids (PL) and triglycerides (TG) in plasma and liver, in rats (n=15) implanted with a colorectal tumour (Ward) and treated with irinotecan (CPT‐11). Once tumour was established (2cm 3 )CPT‐11 (100mg/kg/day) was administered on 3 consecutive days. Blood and liver were collected 1d and 7d later. A Folch method was used to isolate fatty acids from liver and plasma and thin layer chromatography used to separate TG and PL. Types and amounts of fatty acids were determined using gas chromatography. Liver TG contained 50% less saturated fatty acid 1d post treatment compared with non‐treated rats (p<0.05). Higher C22:4n‐6 and C22:5n‐6 were observed 7 days after treatment, compared with other groups in liver PL (p<0.05). Total plasma PL, C18:0, C18:2n‐6, C20:5n‐3 and total saturated fatty acid decreased 25%, rats treated with chemotherapy when compared with untreated groups (p<0.05). There were no differences in amount or types of fatty acids in plasma TG. The results of this study have implications for dietary intervention during treatment for cancer. This research project was funded by the Canadian Institute of Health Research.